Drug profile · INN
pimecrolimus
ELIDEL
pimecrolimus (ELIDEL) is a fk506-binding protein 1a inhibitor. Associated with Viatris Pharmaceuticals Co.,. Route of administration: topical. Current US regulatory status: approved.
Drug details — pimecrolimus
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 2
- Programs
- 6
- Data quality
- 0.84
Quick answer
pimecrolimus (ELIDEL) is a fk506-binding protein 1a inhibitor. Associated with Viatris Pharmaceuticals Co.,. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
FK506-binding protein 1A inhibitor
Primary target: Peptidyl-prolyl cis-trans isomerase FKBP1A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is pimecrolimus?
pimecrolimus (ELIDEL) is a fk506-binding protein 1a inhibitor. Associated with Viatris Pharmaceuticals Co.,. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for pimecrolimus?
ELIDEL is a marketed brand name for pimecrolimus. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pimecrolimus?
pimecrolimus has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.